Suppr超能文献

相似文献

1
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.
J Am Acad Dermatol. 2011 Jul;65(1):25-34. doi: 10.1016/j.jaad.2010.09.016. Epub 2011 Apr 29.
6
The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients.
Rheumatology (Oxford). 2019 May 1;58(5):786-791. doi: 10.1093/rheumatology/key386.
7
Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Rheumatology (Oxford). 2010 Sep;49(9):1726-33. doi: 10.1093/rheumatology/keq153. Epub 2010 May 25.
8
Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features.
J Am Acad Dermatol. 2018 Apr;78(4):776-785. doi: 10.1016/j.jaad.2017.12.010. Epub 2017 Dec 9.
9
Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study.
J Dtsch Dermatol Ges. 2023 Jul;21(7):741-748. doi: 10.1111/ddg.15089. Epub 2023 May 23.
10
The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
Rheumatology (Oxford). 2010 Mar;49(3):433-40. doi: 10.1093/rheumatology/kep375. Epub 2009 Dec 16.

引用本文的文献

1
Two cases of ulcerative dermatomyositis with negative antimelanoma differentiation-associated gene 5 antibody.
JAAD Case Rep. 2025 Apr 3;60:135-138. doi: 10.1016/j.jdcr.2025.02.046. eCollection 2025 Jun.
5
Utility of Myositis-Specific Autoantibodies for Treatment Selection in Myositis.
Curr Treatm Opt Rheumatol. 2022 Dec;8(4):105-116. doi: 10.1007/s40674-022-00198-1. Epub 2022 Sep 28.
7
Anti-nuclear Matrix Protein 2 Antibody-Positive Dermatomyositis Relapse With Preceding Panniculitis.
Cureus. 2025 Feb 6;17(2):e78622. doi: 10.7759/cureus.78622. eCollection 2025 Feb.
9
10
A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade.
BMC Rheumatol. 2025 Jan 26;9(1):9. doi: 10.1186/s41927-025-00460-8.

本文引用的文献

3
Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Rheumatology (Oxford). 2010 Sep;49(9):1726-33. doi: 10.1093/rheumatology/keq153. Epub 2010 May 25.
4
Interferon-induced helicase (IFIH1) polymorphism with systemic lupus erythematosus and dermatomyositis/polymyositis.
Mod Rheumatol. 2010 Oct;20(5):466-70. doi: 10.1007/s10165-010-0311-9. Epub 2010 May 14.
5
The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
Rheumatology (Oxford). 2010 Mar;49(3):433-40. doi: 10.1093/rheumatology/kep375. Epub 2009 Dec 16.
6
The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis.
J Cutan Pathol. 2010 Jun;37(6):659-71. doi: 10.1111/j.1600-0560.2009.01443.x. Epub 2009 Nov 4.
7
Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity.
Pharmacol Ther. 2009 Nov;124(2):219-34. doi: 10.1016/j.pharmthera.2009.06.012. Epub 2009 Jul 15.
9
Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression.
Rheumatology (Oxford). 2009 Jun;48(6):607-12. doi: 10.1093/rheumatology/kep078.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验